MedTrace Logo

Neuroendocrine Neoplasms Methylation Based Classifier - The NEMESIs-study

NCT05013957 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 32

Last updated 2025-01-29

No results posted yet for this study

Summary

Neuroendocrine neoplasms (NEN) are rare tumors that mainly occur in the gastrointestinal tract and the lungs. The currently available diagnostic and prognostic markers do not adequately represent the diversity of these tumors. Methylation analyzes of the tumor DNA represent a new, promising approach.

The aim of this project is therefore to improve the diagnostic and prognostic evaluation of neuroendocrine neoplasms by means of methylation analysis of the tumor DNA. On the one hand, existing tumor samples from the biobank of Basel University Hospital are evaluated, on the other hand, patients who are undergoing an operation will be prospectively inquired

Conditions

Interventions

DIAGNOSTIC_TEST

Methylation analysis

Methylation analysis

Sponsors & Collaborators

  • University Hospital, Basel, Switzerland

    lead OTHER

Eligibility

Min Age
18 Years
Max Age
100 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-01-01
Primary Completion
2024-12-30
Completion
2024-12-30

Countries

  • Switzerland

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05013957 on ClinicalTrials.gov